New appointment at Cortria
This article was originally published in Scrip
Cortria (US) has named Dr Gene Cefali senior vice-president of clinical pharmacology and formulation development. Dr Cefali was previously vice-president of lead optimisation at Kos Pharmaceuticals (acquired by Abbott Laboratories). He will join Cortria's development team focused on advancing TRIA-662 as a new drug candidate for the treatment of dyslipidaemia.